Obesity and prostatic cancer


Cite item

Full Text

Abstract

References

  1. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 2003; 348: 1625-1638.
  2. Flegal K. M., Carroll M. D., Ogden C. L., Johnson C. L. Prevalence and trends in obesity among US adults, 1999-2000. J. A. M. A. 2002; 288: 1723-1727.
  3. Peytremann-Bridevaux I., Faeh D., Santos-Eggimann B. Prevalence of overweight and obesity in rural and urban settings of 10 European countries. Prev. Med. 2007; 44: 442-446.
  4. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2007. Cancer J. Clin. 2007; 57: 43-66.
  5. Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. Cancer J. Clin. 2005; 55: 74-108.
  6. Buschemeyer W. C. 3-rd, Freedland S. J. Obesity and prostate cancer: epidemiology and clinical implications. Eur. Urol. 2007; 52: 331-343.
  7. Satia-Abouta J., Patterson R. E., Schiller R. N., Kristal A. R. Energy from fat is associated with obesity in U. S. men: results from the Prostate Cancer Prevention Trial. Prev. Med. 2002; 34: 493-501.
  8. Nelson W. G., De Marzo A. M., Isaacs W. B. Prostate cancer. N. Engl. J. Med. 2003; 349: 366-381.
  9. Available at URL: http:www.m-w.com/. Accessed March 17, 2007.
  10. Veierod M. B., Laake P., Thelle D. S. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int. J. Cancer 1997; 73: 634-638.
  11. Engeland A., Tretli S., Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br. J. Cancer 2003; 89: 1237-1242.
  12. Andersson S. O., Wolk A., Bergstrom R. et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J. Natl. Cancer Inst. 1997; 89: 385-389.
  13. Putnam S. D., Cerhan J. R., Parker A. S. et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann. Epidemiol. 2000; 10: 361-369.
  14. Schuurman A. G., Goldbohm R. A., Dorant E., van den Brandt P. A. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am. J. Epidemiol. 2000; 151: 541-549.
  15. Nilsen T. I., Vatten L. J. Anthropometry and prostate cancer risk: a prospective study of 22248 Norwegian men. Cancer Causes Control 1999; 10: 269-275.
  16. Giovannucci E., Rimm E. B., Liu Y. et al. Body mass index and risk of prostate cancer in U. S. health professionals. J. Natl. Cancer Inst. 2003; 95: 1240-1244.
  17. Macinnis R. J., English D. R. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989-1003.
  18. Rodriguez C., Freedland S. J., Deka A. et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 63-69.
  19. Wright M. E., Chang S. C., Schatzkin A. et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684.
  20. Gong Z., Neuhouser M. L., Goodman P. J. et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1977-1983.
  21. Gong Z., Agalliu I., Lin D. W. et al. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192-1202.
  22. Scales C. D. Jr., Curtis L. H., Norris R. D. et al. Relationship between body mass index and prostate cancer screening in the United States. J. Urol. (Baltimore) 2007; 177: 493-498.
  23. Baillargeon J., Pollock B. H., Kristal A. R. et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103: 1092-1095.
  24. Barqawi A. B., Golden B. K., O'Donnell C. et al. Observed effect of age and body mass index on total and complexed PSA; analysis from a national screening program. Urology 2005; 65: 708-712.
  25. Gray M. A., Delahunt B., Fowles J. R. et al. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res. 2004; 24: 2069-2072.
  26. Ku J. H., Kim M. E., Lee N. K. et al. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 2003; 61: 132-136.
  27. Werny D. M., Thompson T., Saraiya M. et al. Obesity is negatively associated with prostate-specific antigen in U. S. men. 2001-2004. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 70-76.
  28. Fowke J. H., Motley S. S., Wills M. et al. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostate intraepithelial neoplasia. Cancer Causes Control 2007; 18: 375-384.
  29. Hutterer G., Perrotte P., Gallina A. et al. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. Eur. J. Cancer 2007; 43: 1180-1187.
  30. Freedland S. J., Humphreys E. B., Mangold L. A. et al. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J. Urol. (Baltimore) 2006; 176: 1404-1408.
  31. Barfez L. L., Hamilton R. J., Vollmer R. T. et al. Can hemodilution explain the lower PSA concentrations among obese men. In: American Urological Associatioln. Annual Meeting 2007. Anaheim, CA; 2007. 13-17.
  32. Dahle S. E., Chokkalingam A. P., Gao Y. T. et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol. (Baltimore) 2002; 168: 599-604.
  33. Freedland S. J., Platz E. A., Presti J. C. Jr. et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J. Urol. (Baltimore) 2006; 175:500-504.
  34. Kranse R., Beemsterboer P., Rietbergen J. et al. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999; 39: 316-322.
  35. Freedland S. J., Aronson W. J., Kane C. J. et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J. Clin. Oncol. 2004; 22: 446-453.
  36. Amling C. L., Riffenburgh R. H., Sun L. et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J. Clin. Oncol. 2004; 22: 439-445.
  37. Bassett W. W., Cooperberg M. R., Sadetsky N. et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data drom CaPSURE. Urology 2005; 66: 1060-1065.
  38. Merrick G. S., Butler W. M., Wallner K. E. et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 2005; 65: 95-100.
  39. Strom S. S., Kamat A. M., Gruschkus S. K. et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 2006; 107: 631-639.
  40. Freedland S. J., Grubb K. A., Yiu S. K. et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J. Urol. (Baltimore) 2005; 174: 1798-1801; discus.: 801.
  41. Fitzsimons N., Sun L., Dahm P. et al. A single institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke prostate center database. Presented at the SESAUA, Orlando, FL; 2007.
  42. Millender L. E., Aubin M., Pouliot J. et al. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 59: 6-10.
  43. Freedland S. J., Terris M. K., Presti J. C. Jr. et al. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J. Urol. (Baltimore) 2004; 172: 520-524.
  44. Rodriguez C., Patel A. V., Calle E. E. et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol. Biomarkers Prev. 2001; 10: 345-353.
  45. Wright M. E., Chang S. C., Albanes D. et al. The association of obesity with risk of localized, advanced, and fatal prostate cancer in the NIH-AARP Diet and Health Study. Proc. Am. Assoc. Cancer Res. 2006; 47: 475.
  46. Okasha M., McCarron P., McEwen J., Smith G. D. Body mass index in young adulthood and cancer mortality: a retrospective cohort study. J. Epidemiol. Commun. Hlth 2002; 56: 780-784.
  47. Shuldiner A. R., Yang R., Gong D. W. Resistin, obesity and insulin resistance - the emerging role of the adipocyte as an endocrine organ. N. Engl. J. Med. 2001; 345: 1345-1346.
  48. Trujillo M. E., Scherer P. E. Adipose tissue-derived factors: impact on health and disease. Endocr. Rev. 2006; 27: 762-778.
  49. Calle E. E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004; 4: 579-591.
  50. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 2006; 50: 935-939.
  51. Massengill J. C., Sun L., Moul J. W. et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol. (Baltimore) 2003; 169: 1670-1675.
  52. Schatzl G., Madersbacher S., Thurridl T. et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52-58.
  53. Platz E. A., Leitzmann M. F., Rifai N. et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 1262-1269.
  54. Severi G., Morris H. A., MacInnis R. J. et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 86-91.
  55. Algarte-Genin M., Cussenot O., Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur. Urol. 2004; 46: 285-294; discus.: 94-95.
  56. Baillargeon J., Rose D. P. Obesity, adipokines, and prostate cancer (review). Int. J. Oncol. 2006; 28: 737-745.
  57. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Hormone Metabol. Res. 2003; 35: 694-704.
  58. Bosland M. C., Ford H., Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol.l Carcinogenesis 1995; 16: 1311-1317.
  59. Drago J. R. The induction of NB rat prostatic carcinomas. Anticancer Res. 1984; 4: 255-256.
  60. Leav I., Merk F. B., Kwan P. W., Ho S. M. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989; 15: 23-40.
  61. Hsing A. W., Tsao L., Devesa S. S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 2000; 85: 60-67.
  62. Price D., Stein B., Sieber P. et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J. Urol. (Baltimore) 2006; 176: 965-970; discus.: 70-71.
  63. Hubbard J. S., Rohrmann S., Landis P. K. et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004; 63: 253-258.
  64. Tande A. J., Platz E. A., Folsom A. R. The metabolic syndrome is associated with reduced risk of prostate cancer. Am. J. Epidemiol. 2006; 164: 1094-1102.
  65. Laukkanen J. A., Laaksonen D. E., Niskanen L. et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol. Biomarkers Prev. 2004; 13: 1646-1650.
  66. Lund Haheim L., Wisloff T. F., Holme I., Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am. J. Epidemiol. 2006; 164: 769-774.
  67. Hsing A. W., Chua S. Jr., Gao Y. T. et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J. Natl. Cancer Inst. 2001; 93: 783-789.
  68. Tulinius H., Sigfusson N., Sigvaldason H. et al. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 863-873.
  69. Hsing A. W., Gao Y. T., Chua S. Jr. et al. Insulin resistance and prostate cancer risk. J. Natl. Cancer Inst. 2003; 95: 67-71.
  70. Augustin L. S., Galeone C., Dal Maso L. et al. Glycemic index, glycemic load and risk of prostate cancer. Int. J. Cancer 2004; 112: 446-450.
  71. Ho G. Y., Melman A., Liu S. M. et al. Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br. J Cancer 2003; 88: 263-269.
  72. Scheen A. J. Pathophysiology of insulin secretion. Ann. Endocrinol. (Paris) 2004; 65: 29-36.
  73. Bonovas S., Filioussi K., Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-1078.
  74. Kaaks R., Lukanova A., Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostat. Dis. 2000; 3: 157-172.
  75. Nam S. Y., Lee F. J., Kim K. R. et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int. J. Obes. Relat. Metabol. Disord. 1997; 21: 355-359.
  76. Holmes M. D., Pollak M. N., Hankinson S. E. Lifestyle correlates of plasma insulin-like growth factor I and insulinlike growth factor binding protein 3 concentrations. Cancer Epidemiol. Biomarkers Prev. 2002; 11: 862-867.
  77. Iwamura M., Sluss P. M., Casamento J. B., Cockett A. T. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993; 22: 243-252.
  78. Chan J. M., Stampfer M. J., Giovannucci E. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-566.
  79. Stattin P., Bylund A., Rinaldi S. et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J. Natl. Cancer Inst. 2000; 92: 1910-1917.
  80. Wolk A., Mantzoros C. S., Andersson S. O. et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 1998; 90: 911-915.
  81. Shaneyfelt T., Husein R., Bubley G., Mantzoros C. S. Hormonal predictors of prostate cancer: a meta-analysis. J. Clin. Oncol. 2000; 18: 847-853.
  82. Renehan A. G., Zwahlen M., Minder C. et al. Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353.
  83. Shi R., Berkel H. J., Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br. J. Cancer 2001; 85: 991-996.
  84. Onuma M., Bub J. D., Rummel T. L., Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J. Biol. Chem. 2003; 278: 42660-42667.
  85. Stattin P., Soderberg S., Hallmans G. et al. Leptin is associated prostate cancer risk: a nested case-referent study. J. Clin. Endocrinol. 2001; 86: 1341-1345.
  86. Gade-Andavolu R., Cone L. A., Shu S. et al. Molecular interactions of leptin and prostate cancer. Cancer J. 2006; 12: 201-206.
  87. Stattin P., Kaaks R., Johansson R. et al. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2003; 12: 474-475.
  88. Baillargeon J., Platz E. A., Rose D. P. et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1331-1335.
  89. Chang S., Hursting S. D., Contois J. H. et al. Leptin and prostate cancer. Prostate 2001; 46: 62-67.
  90. Saglam K., Aydur E., Yilmaz M., Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J. Urol. (Baltimore) 2003; 169: 1308-1311.
  91. Freedland S. J., Sokoll L. J., Mangold L. A. et al. Serum leptin and pathological findings at the time of radical prostatectomy. J. Urol. (Baltimore) 2005; 173: 773-776.
  92. Ribeiro R., Vasconcelos A., Costa S. et al. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 2004; 59: 268-274.
  93. Brakenhielm E., Veitonmaki N., Cao R. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. USA 2004; 101: 2476-2481.
  94. Freedland S. J., Sokoll L. J., Platz E. A. et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol. (Baltimore) 2005; 174: 1266-1270.
  95. Goktas S., Yimaz M. I., Caglar K. et al. Prostate cancer and adiponectin. Urology 2005; 65: 1168-1172.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies